Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 34, 2015, Pages 10780-10785

  Burton, Samantha L ^a   Kilgore, Katie M ^a   Smith, S Abigail ^a   Reddy, Sharmila ^a   Hunter, Eric ^a,b   Robinson, Harriet L ^c   Silvestri, Guido ^a,b   Amara, Rama R ^a,b   Derdeyn, Cynthia A ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Research and Development   (United States)

Author keywords

Neutralization; SIV; Vaccine

Indexed keywords

CD40 LIGAND; D40LD40LMM VACCINE; DDMM VACCINE; DGDGMM VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MMM VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; GENETIC VARIABILITY; IC50; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; BLOOD; ENVELOPE GENE; GENETICS; IMMUNIZATION; IMMUNOLOGY; MOLECULAR GENETICS; MUCOSAL IMMUNITY; NUCLEOTIDE SEQUENCE; PATHOGENICITY; SEQUENCE ALIGNMENT; SERODIAGNOSIS; VACCINATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS ANKARA;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BASE SEQUENCE; GENE PRODUCTS, ENV; GENES, ENV; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; INHIBITORY CONCENTRATION 50; MACACA MULATTA; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SAIDS VACCINES; SEQUENCE ALIGNMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

EID: 84940417376     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1509731112     Document Type: Article

References (63)

1. Doria-Rose NA, et al.; NISC Comparative Sequencing Program (2014) Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509(7498):55-62.
2. Liao HX, et al.; NISC Comparative Sequencing Program (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496(7446):469-476.
3. Haynes BF, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366(14):1275-1286.
4. Derdeyn CA, Moore PL, Morris L (2014) Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS 9(3):210-216.
5. Shibata R, et al. (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5(2):204-210.
6. Mascola JR, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6(2):207-210.
7. Hessell AJ, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15(8):951-954.
8. Parren PW, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75(17):8340-8347.
9. Baba TW, et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6(2):200-206.
10. Pegu A, et al. (2014) Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 6(243):243ra88.
11. Moldt B, et al. (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 109(46):18921-18925.
12. Shingai M, et al. (2014) Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211(10):2061-2074.
13. Rudicell RS, et al.; NISC Comparative Sequencing Program (2014) Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88(21):12669-12682.
14. Hessell AJ, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5(5):e1000433.
15. Letvin NL, et al. (2011) Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 3(81):81ra36.
16. Flatz L, et al. (2012) Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol 86(15):7760-7770.
17. Patel V, et al. (2013) DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci USA 110(8):2975-2980.
18. Roederer M, et al. (2014) Immunological and virological mechanisms of vaccinemediated protection against SIV and HIV. Nature 505(7484):502-508.
19. Kwa S, et al. (2014) CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol 88(17):9579-9589.
20. Lai L, et al. (2011) Prevention of infection by a granulocyte-macrophage colonystimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 204(1):164-173.
21. Lai L, et al. (2012) SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 30(9):1737-1745.
22. Rolland M, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490(7420):417-420.
23. Rolland M, et al. (2011) Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 17(3):366-371.
24. Derdeyn CA, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303(5666):2019-2022.
25. Haaland RE, et al. (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5(1): e1000274.
26. Boeras DI, et al. (2011) Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc Natl Acad Sci USA 108(46):E1156-E1163.
27. Lopker M, et al. (2013) Heterogeneity in neutralization sensitivity of viruses comprising the SIVsmE660 isolate and vaccine challenge stock. J Virol 87(10):5477-5492.
28. Kilgore KM, et al. (2015) Characterization and implementation of a diverse SIVsm envelope panel in the assessment of neutralizing antibody breadth elicited in rhesus macaques by multi-modal vaccines expressing the SIVmac239 ENVELOPE. J Virol 89(16):8130-8151.
29. Kim JH, Excler JL, Michael NL (2015) Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 66:423-437.
30. Tomaras GD, Haynes BF (2014) Advancing toward HIV-1 vaccine efficacy through the intersections of immune correlates. Vaccines (Basel) 2(1):15-35.
31. Lewis GK, DeVico AL, Gallo RC (2014) Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development. Proc Natl Acad Sci USA 111(44): 15614-15621.
32. Barouch DH, et al. (2012) Vaccine protection against acquisition of neutralizationresistant SIV challenges in rhesus monkeys. Nature 482(7383):89-93.
33. DeVico A, et al. (2007) Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA 104(44):17477-17482.
34. Eugene HS, Pierce-Paul BR, Cragio JK, Ross TM (2013) Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Virol J 10:102.
35. Thomas MA, et al. (2014) HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology 471-473:81-92.
36. Fouts TR, et al. (2015) Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci USA 112(9):E992-E999.
37. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP (2014) Immunology. Immune activation with HIV vaccines. Science 344(6179):49-51.
38. Staprans SI, et al. (2004) Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 101(35):13026-3031.
39. Carnathan DG, et al. (2015) Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci USA 112(2):518-523.
40. Tenbusch M, et al. (2012) Risk of immunodeficiency virus infection may increase with vaccine-induced immune response. J Virol 86(19):10533-10539.
41. Ma D, et al.; International Vervet Research Consortium (2013) SIVagm infection in wild African green monkeys from South Africa: Epidemiology, natural history, and evolutionary considerations. PLoS Pathog 9(1):e1003011.
42. Chahroudi A, et al. (2014) Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques. PLoS Pathog 10(3):e1003958.
43. Pandrea I, et al. (2008) Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. J Virol 82(11):5501-5509.
44. Carlson JM, et al. (2014) HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 345(6193):1254031.
45. Sagar M, et al. (2004) Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS 18(4):615-619.
46. Blish CA, et al. (2014) Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection. J Virol 88(10):5894-5899.
47. Hessell AJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101-104.
48. Bernard-Stoecklin S, Gommet C, Cavarelli M, Le Grand R (2014) Nonhuman primate models for cell-associated simian immunodeficiency virus transmission: The need to better understand the complexity of HIV mucosal transmission. J Infect Dis 210(Suppl 3):S660-S666.
49. Sagar M (2014) Origin of the transmitted virus in HIV infection: Infected cells versus cell-free virus. J Infect Dis 210(Suppl 3):S667-S673.
50. Whaley KJ, Mayer KH (2014) Strategies for preventing mucosal cell-associated HIV transmission. J Infect Dis 210(Suppl 3):S674-S680.
51. Sallé B, et al. (2010) Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J Infect Dis 202(3):337-344.
52. Malbec M, et al. (2013) Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med 210(13):2813-2821.
53. Abela IA, et al. (2012) Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 8(4):e1002634.
54. Goepfert PA, et al.; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network (2014) Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 210(1):99-110.
55. Iyer SS, et al. (2015) Codelivery of envelope protein in alum with MVA vaccine induces CXCR3-biased CXCR5+ and CXCR5- CD4 T cell responses in rhesus macaques. J Immunol 195(3):994-1005.
56. Salazar-Gonzalez JF, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82(8):3952-3970.
57. Li B, et al. (2010) Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies. J Virol 84(12):6248-6253.
58. Rong R, et al. (2009) Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 5(9):e1000594.
59. Li B, et al. (2006) Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80(11):5211-5218.
60. Murphy MK, et al. (2013) Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 9(2):e1003173.
61. Lynch RM, et al. (2011) The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol 85(2):905-915.
62. Rong R, et al. (2007) Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81(3):1350-1359.
63. Rong R, et al. (2007) Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 81(11):5658-5668.